Teva beats Copaxone forecasts; Bayer HealthCare churns up 19% sales growth;

@FiercePharma: Investors cheer Abaxis but trounce IDEXX on quarterly diagnostics performance. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: IOYMI: Napp Pharmaceuticals says it is offering England's NHS Remsima for as much as 60% less than Remicade. Article | Follow @EricPFierce

@CarlyHFierce: GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surge. Article | Follow @CarlyHFierce

> Teva ($TEVA) beat profit forecasts and raised its outlook on Thursday, in part thanks to a revenue beat from multiple sclerosis med Copaxone. Report

> Bayer's healthcare unit once again drove the German company's sales, with 19.2% growth in that business, to €5.65 billion, overshadowing currency setbacks in its CropScience unit. Report

> Backers of a referendum targeting a reduction in prescription drug costs in California said Wednesday that they'd rounded up more than enough signatures to place their measure on the November 2016 ballot. Report

Medical Device News

@FierceMedDev: Cleveland Clinic developing catheter for delivery of chemotherapy directly into the brain. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Theranos authorized new shares that would value the co. at $10B, 3 days before the WSJ article came out. Story | Follow @EmilyWFierce

> Startup Qvella gets $20M Series A to develop rapid pathogen detection test. Story

> Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. News

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Interesting that most of the $PFE/$AGN discussion is around the mechanics of a deal, rather than a backlash against another megamerger. | Follow @JohnCFierce

> Frazier unveils a $262M pure-play biotech venture fund. Story

> Biotech IPOs are staggering as the bulls begin to fade back. Report

> Ultragenyx launches an RNA collaboration with upstart Arcturus. Article

CRO News

> Icon ekes out another quarter of growth despite currency woes. More

> INC boosts its outlook after another big revenue quarter. Report

> Parexel's profits slide as it slashes costs. Story

> Novartis, Qualcomm back trial startup's $6.5M round. Item

> PRA upgrades its Dutch R&D hub with eyes on bioanalytics. Article

Pharma Manufacturing News

> Pfizer and GSK to work together on continuous manufacturing. Item

> Novartis' Sandoz plants in India cited in warning letter. More

> Saline producers face call for FTC probe into shortage, rising prices. Report

> States want FDA to quit seizing their execution drugs. Story

> Aurobindo moves forward with plans for new U.S. plant. Article

Pharma Asia News

> Novartis to close one Indian manufacturing plant as FDA warning bites. Article

> Lupin hopes for more U.S. approvals as earnings drop 35%. Item

> Health insurance companies still being targeted by Chinese hackers. Story

> Cough syrup abuse gets India's attention. More

> BMS sees sharper hep C competition in Japan in Q3. Report

And Finally... Former Merck & Co. ($MRK) CEO Roy Vagelos has amassed a net worth of $1.3 billion from his service on fast-growing Regeneron's board. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.